Home | Bionomics – Clinical-stage biopharmaceutical company
Bionomics is a global, clinical-stage biotechnology company focused on developing novel, first-in-class, ion channel modulators to treat patients suffering from serious central nervous system …
Bionomics Limited (BNOX) - Yahoo Finance
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
Bionomics Limited (BNOX): Stock Soars Over 162% Following …
2024年11月5日 · Bionomics Limited (Nasdaq: BNOX), a clinical-stage biotechnology company based in Australia and the U.S., has become a focal point in the biotech sector as its stock …
Bionomics - Wikipedia
Bionomics (Greek: bio = life; nomos = law) has two different meanings: the first is the comprehensive study of an organism and its relation to its environment. As translated from the …
Bionomics Announces Successful End-of-Phase 2 Meeting with …
2024年7月31日 · We believe BNC210 can potentially transform the standard-of-care in PTSD, a serious disorder impacting about 7% of Americans during their lifetime. Followings the recent …
Bionomics Announces Positive Topline Results from the Phase
2023年9月28日 · Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute …
Bionomics Limited Announces Private Placement of up to $70.0 …
2024年5月31日 · ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical …
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with
2024年7月18日 · Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients …
Bionomics Provides a Review of 2023 and of 2024 Plans
2024年1月22日 · Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute …
Bionomics Receives Milestone Payment of AUS$1M from Carina …
2024年11月4日 · Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients …